Key result
STEMI patients and those developing acute heart failure during myocardial infarction had significantly higher levels of platelet- and monocyte-derived circulating microparticles compared to NSTEMI patients and those without heart failure.
Population
200 patients aged 75±4 years, evaluated 2-8 weeks after suffering an acute myocardial infarction.
Design
Cross-sectional
Follow-up
2-8 weeks post-AMI
Authors
Loading...
TF+ platelet- and monocyte-derived cMPs associate with STEMI and post-AMI HF; hypothesis-generating for thrombotic burden, needs prospective validation.
Cross-Sectional (n=200)
No
p-value: p=0.006
Platelet- and monocyte-derived circulating microparticles carrying tissue factor remain elevated in AMI patients and correlate with infarct severity and the development of heart failure.
Chiva‐Blanch et al. (2017) conducted a cross-sectional in Acute myocardial infarction (AMI) (n=200). ST-elevation myocardial infarction (STEMI) and acute heart failure vs. Non-ST-elevation myocardial infarction (NSTEMI) and no acute heart failure was evaluated on Levels of platelet-derived circulating microparticles (CD31+/CD42b+/AV+) (p=0.006). STEMI patients and those developing acute heart failure during myocardial infarction had significantly higher levels of platelet- and monocyte-derived circulating microparticles compared to NSTEMI patients and those without heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: